Novel Diabetic Wound Treatment Turns Cells Into Manufacturers
Researchers at Texas A&M have created a novel wound dressing for diabetic foot ulcers that leverages an interwoven extracellular matrix produced by human cells, then strips the cells away, leaving a purely biological scaffold. The approach sidesteps the immune‑rejection and variability issues tied to pig‑derived or cadaver skin grafts. By using a framework to guide cell growth, the team can generate uniform structures that can be washed clean of cells. Scaling the process in bioreactors could deliver unlimited, standardized material for chronic wound care.
StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts
Revolution Medicines reported Phase III RASolute 302 results showing its oral RAS inhibitor daraxonrasib extended median overall survival to 13.2 months in previously treated metastatic pancreatic ductal adenocarcinoma, versus 6.7 months for standard chemotherapy (HR 0.40, p < 0.0001). The data sparked a...
Searches up 900%: Google Faces Influx of Illegal Peptide Ads
Google is facing a surge in advertisements for illegal synthetic peptides, with searches for terms like BPC‑157, GHK‑CU and Retatrutide jumping up to 900% over the past year. The ads violate Google’s own policies and Australian law, prompting the company...
Can a Common Parasite Medication Calm the Brain’s Stress Circuitry During Alcohol Withdrawal?
Researchers at UC San Diego discovered that rodents with high P2rx4 gene expression exhibit markedly increased alcohol consumption during withdrawal. Administering the antiparasitic drug ivermectin produced a dose‑dependent reduction in lever‑pressing for alcohol, especially in animals that responded behaviorally. Electrophysiological...
20 Years Of Priority Review Vouchers, A Tool For Spurring Needed Drugs
The U.S. priority review voucher (PRV) program, created in 2007 to spur drug development for neglected tropical diseases (NTDs), has turned into a lucrative market incentive, with vouchers fetching nine‑figure sums. A landmark case is MDGH’s moxidectin, the first new...
STAT+: The Race to Catch KRAS, Pancreatic Cancer’s ‘Greasy Ball,’ and Create the Most Promising Drug in Decades
A new wave of KRAS‑targeted therapies is reshaping pancreatic cancer treatment after decades of failure. Revolution Medicines’ daraxonrasib, a next‑generation KRAS inhibitor, delivered dramatic survival benefits for patient Leanna Stokes, who enrolled in a clinical trial. The drug’s success has...
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
TG Therapeutics was downgraded from Strong Buy to Buy after a 17% rally that brought its valuation closer to fundamentals. The company’s flagship MS drug, Briumvi IV, continues to capture market share, while a fully enrolled sub‑cutaneous trial could double...
Quality Metrics for Drug Manufacturing
The FDA is advancing a Quality Metrics Reporting Program to collect objective manufacturing data from drug producers. By analyzing these metrics, the agency aims to enhance risk‑based surveillance, predict shortages, and streamline inspections. The initiative builds on a decade of...
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
Definium Therapeutics welcomed the White House’s new executive order that aims to speed research, regulatory review, and access to innovative mental‑health treatments, including psychedelics. The order directs federal agencies to streamline pathways and boost cross‑agency collaboration. Definium highlighted its DT120...
Three Gene Therapy Pioneers Just Won the Breakthrough Prize. This Is Their Story
Three pioneering scientists—Jean Bennett, Albert Maguire, and David J. Wilson—have been honored with the 2026 Breakthrough Prize in Life Sciences for their work on Luxturna, the first gene‑therapy approved by the U.S. Food and Drug Administration. Luxturna treats a rare...
Pliant Therapeutics Announces Presentation of Updated Data From the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid...
Pliant Therapeutics presented updated Phase 1a/1b data for its integrin inhibitor PLN‑101095 combined with pembrolizumab at the 2026 AACR meeting. In ICI‑refractory solid‑tumor patients, the regimen produced an average 89% tumor reduction and a median treatment duration of 19 months among...
Scalable Flow Reactors for Stable Biofilm Formation and Continuous Whole‐Cell Catalysis
Researchers have unveiled a modular, scalable microfluidic reactor that uses flow‑induced deposition to form robust E. coli biofilms directly from suspended cells. By coupling pillar‑based designs with computational fluid dynamics, the team mapped microscale flow features that drive cell attachment,...
These Alzheimer’s Drugs Were Supposed to Revolutionize the Way We Fight the Disease. The Reality Is More Complicated.
A new Cochrane Library review casts doubt on the clinical value of Leqimbi and Kisunla, the two Alzheimer’s drugs hailed as breakthroughs in recent years. The analysis of multiple trials finds the medications produce little to no improvement in cognition,...
Lupin Receives Form 483 After USFDA Inspection of Somerset Unit
Lupin Ltd disclosed that the U.S. Food and Drug Administration issued a Form 483 after inspecting its Somerset, New Jersey manufacturing site from April 13‑17, 2026. The FDA cited three observations that may represent violations of the FD&C Act. Lupin said it will address...
Managing Infection Risks in BCMA Bispecific Antibody Therapy: Ajay K. Nooka, MD, MPH
The FDA granted full approval to teclistamab (Tecvayli), a BCMA bispecific antibody for relapsed/refractory multiple myeloma, despite grade 3‑4 infection rates of 50‑60 percent observed in early trials. Ajay K. Nooka, MD, MPH, explained that these infections occurred largely during the COVID‑19 pandemic...
Lilly CEO Sees Weight-Loss Drugs Reaching About Half of Potential Users at Peak
Eli Lilly CEO David Ricks told investors that GLP‑1 weight‑loss drugs will likely reach only about half of the 500 million people worldwide who could benefit, due to institutional and cost barriers. He noted that today roughly one in ten eligible patients...
Pfizer Vaccine Safe, Effective in Juvenile Inflammatory Disease
A multi‑center trial published this week confirms that Pfizer's mRNA COVID‑19 vaccine is both safe and effective for children suffering from juvenile inflammatory diseases such as juvenile idiopathic arthritis and inflammatory bowel disease. The study tracked 312 participants aged 5‑17,...
Trump Expected to Loosen Restrictions on Psychedelic Drugs
President Trump is set to sign an executive order that will loosen federal restrictions on psychedelic drugs such as LSD, ecstasy and psilocybin. The order earmarks $50 million for state‑level ibogaine research, with Texas slated to receive the first grant. It...
How Nanomedicine Gets Inside Your Cells and Treats You From the Inside Out
Nanomedicine is moving from concept to clinic as researchers use lipid‑nanoparticle carriers to deliver synthetic mRNA and siRNA directly into patient cells. The approach lets liver cells produce missing proteins such as factor VIII for hemophilia A, while silencing harmful proteins like...
GLP-1 Receptor Agonists and Risk of Suicide or Suicide Attempts – A Nationwide Cohort and Self-Controlled Case Series Study
A nationwide Danish registry study examined whether glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) increase suicide or suicide attempts compared with active comparators—SGLT‑2 and DPP‑4 inhibitors. Across two new‑user cohorts totaling over 200,000 GLP‑1 RA initiators, adjusted hazard ratios showed no elevated risk...
Major UKHSA Study Finds Maternal RSV Vaccination Reduces Infant Hospitalization Risk by More Than 80%
Researchers from the UK Health Security Agency presented the largest real‑world evaluation of maternal RSV immunisation, showing that infants whose mothers received the bivalent Prefusion F vaccine at least two weeks before delivery experienced an 81.3% drop in RSV‑related hospitalisations. The...
New PARP Inhibitor Resistance Mechanisms Found in Ovarian Cancer
A recent British Journal of Cancer study uncovers drug‑specific resistance mechanisms to PARP inhibitors in ovarian cancer, highlighting alterations in PARP trapping, replication‑fork protection, and chromatin‑remodeling. The research shows that resistance is not limited to homologous recombination restoration but involves...
Mammary Organoid Depot Enables Post-Surgery Chemo, Regeneration
Researchers have created a mammary organoid‑based depot that delivers a pH‑responsive doxorubicin prodrug directly to the surgical site while simultaneously regenerating breast tissue. The engineered organoids mimic lactation, loading drug‑laden lipid droplets into milk‑fat globules that are secreted locally, achieving...
DTE Producer Hoping For FDA Leniency, BLA Approval
The FDA announced it will exercise enforcement discretion for animal‑derived desiccated thyroid extract (DTE), allowing the product to stay on the market even though it is classified as an unapproved biologic. Producers of DTE welcomed the move, noting it preserves...
Co-Pay Models and AFPs Shift Costs but Raise Access Concerns: Patty Taddei-Allen, PharmD, MBA
Co‑pay accumulators, maximizers, and alternative funding programs (AFPs) are gaining traction as insurers and PBMs attempt to curb rising drug costs. While accumulators and maximizers keep the existing benefit design, they shift more out‑of‑pocket expenses onto patients. AFPs, by contrast,...
Nanobody Repairs Misfolded CFTR Inside Cells, Boosting Function in Cystic Fibrosis
Researchers at Charité‑Berlin and the Leibniz FMP have engineered a cell‑penetrating nanobody that binds the F508del mutant CFTR inside lung cells, restoring proper folding and chloride transport. In vitro, the nanobody remained bound for at least 24 hours and rescued channel...
AHA Urges en Banc Review of 4th Circuit’s West Virginia 340B Contract Pharmacy Law Decision
The American Hospital Association (AHA) and allied groups filed an amicus brief on April 17 urging the 4th U.S. Circuit Court of Appeals to rehear en banc a panel ruling that struck down West Virginia’s law protecting 340B contract‑pharmacy arrangements....
Personalized Bioelectrodes Improve Brain Signal Monitoring and Compatibility
Penn State researchers have created 3D‑printed hydrogel bioelectrodes that are customized to an individual’s brain geometry using MRI‑derived models. The honeycomb‑inspired, stretchable design conforms to cortical gyri and sulci far better than conventional stiff, one‑size‑fits‑all probes, delivering higher‑quality electrical signals....
Exploring Untapped Natural Chemistry for Future Medicines
Generare, a Paris‑based tech‑bio startup, is tackling AI drug‑discovery limitations by feeding models with diverse, biologically validated natural compounds from microbes. CEO Guillaume Vandenesch argues that current AI systems rely on narrow synthetic datasets, which restrict therapeutic relevance. The company...
Iris Long, Scientific Mentor to AIDS Activists, Dies at 92
Iris Long, a retired organic chemist, died at 92. She became a scientific mentor for ACT UP in 1987, guiding activists through FDA drug‑approval processes and clinical trial design. Her expertise helped accelerate access to experimental AIDS treatments, earning praise from...
Targeted Gene Delivery Calms Lung Inflammation in Respiratory Infection Mouse Models
Scientists at the University of Cambridge have engineered an adeno‑associated virus (AAV6.2‑CC10) to deliver anti‑inflammatory cytokines directly to mouse lung tissue. The platform achieved sustained, localized expression of IL‑1RA and IL‑10, markedly reducing lung damage and weight loss in influenza...
AMPLIFY Redefines CLL Care: Adam Kittai, MD
The FDA has cleared acalabrutinib (Calquence) combined with venetoclax (Venclexta) as the first all‑oral, fixed‑duration regimen for chronic lymphocytic leukemia. The approval follows the phase 3 AMPLIFY trial, which demonstrated superior progression‑free and overall survival compared with traditional chemoimmunotherapy. The study...
Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026
Soley Therapeutics unveiled preclinical data on STX-6398, a first‑in‑class oral small‑molecule that modulates the previously undruggable CKAP2 pathway, at the AAC 2026 meeting. The compound demonstrated selective anti‑tumor activity in a 300‑cell line panel, with efficacy correlating to CKAP2 protein levels...
Initiation of the Interchangeable Biosimilar Insulin Glargine-Yfgn Among Older Adults
A Pennsylvania study of adults 65 and older found that only 3.7% initiated the interchangeable biosimilar insulin glargine‑yfgn (Semglee or unbranded version) between 2022 and mid‑2023. Initiators were disproportionately rural residents, long‑term‑care (LTC) patients, and those with three or more...
Merck’s Enflonsia Approved in EU for RSV Prevention in Infants Without Weight-Based Dosing
Merck’s long‑acting monoclonal antibody Enflonsia (clesrovimab) received European Commission approval for preventing respiratory syncytial virus (RSV) lower‑respiratory‑tract disease in neonates and infants during their first RSV season. The product is administered as a single fixed 105 mg intramuscular dose, removing the...
Mark Cuban Wants to Bring Drug Manufacturing to Hospitals’ Doorsteps — Literally
Mark Cuban’s Cost Plus Drugs is rolling out modular drug‑manufacturing pods that fit into tractor‑trailers, allowing hospitals to produce injectables and specialty medicines on‑site. The Dallas‑based facility already makes epinephrine, norepinephrine, Pitocin and pediatric cancer drugs, and claims rare‑disease therapies...
Medicine's Next Leap: Delivering Gene Therapies Exactly Where They're Needed
Researchers at the University of Ottawa have shown that small extracellular vesicles (sEVs) can be selected based on their cell of origin to deliver siRNA therapeutics precisely to kidneys and the brain. In mouse models of chronic kidney disease, sEV‑mediated...
FDA-TRACK: Prescription Drug User Fee Act Review Goals Summary
The FDA’s Prescription Drug User Fee Act entered its seventh iteration, PDUFA VII, authorizing the agency to collect user fees from October 2023 through September 2027. The fees are earmarked to accelerate pre‑market drug application reviews and post‑market safety monitoring for both drugs...
Mal-Predict: Machine Learning-Guided Rapid Virtual Screening of Compounds Against Selected Targets of Plasmodium Falciparum Validated Using Molecular Dynamics Simulation
The researchers launched Mal‑Predict, a machine‑learning workflow that used a Random Forest classifier (AUC 0.912) to screen 1.9 million compounds from DrugBank, natural‑product, and Enamine‑Real databases for activity against Plasmodium falciparum targets. Predicted actives were docked and subjected to molecular dynamics simulations,...
Precision Biologics Highlights New AML Target for CAR-NK Therapies
Precision Biologics announced preclinical identification of truncated Core 1 O‑glycans as a novel antigen for acute myeloid leukemia (AML). The glycan‑based target is recognized by the company’s investigational antibody NEO‑201 and was presented as a poster at the AACR 2026 meeting....
Scientists Find Unexpected Immune Pathways for mRNA Cancer Vaccines
Scientists at Washington University demonstrated that mRNA cancer vaccines can elicit potent anti‑tumor T‑cell responses even when the classic cDC1 dendritic cell subset is absent. Using mouse models lacking cDC1, cDC2, or both, they showed that cDC2 cells also prime...
ANDA Litigation Settlements - First Quarter 2026
During Q1 2026, U.S. district courts issued a wave of ANDA litigation settlements covering dozens of branded drugs, from ophthalmic gels to diabetes tablets. Most disputes were dismissed, many with prejudice, while several parties entered license agreements that preserve patent exclusivity....
Marengo Reports Early Phase 2 Activity for Invikafusp Alfa Combination; Advances STAR Program at AACR 2026
Marengo Therapeutics announced early Phase 2 activity for its invikafusp alfa plus sacituzumab govitecan (Trodelvy) combo in metastatic breast cancer, reporting confirmed complete responses in heavily pretreated patients across both triple‑negative and hormone‑receptor‑positive/HER2‑negative cohorts. The interim safety data matched the known profiles...
Kailera IPO Interview: CEO Renaud Talks Biotech Market, China and Obesity Pipeline
Kailera Therapeutics closed a record‑setting $625 million Nasdaq IPO, the largest biotech debut of the year. The company, launched with Bain Capital Life Sciences backing, leverages a portfolio of obesity drug candidates originally sourced from China’s Hengrui Medicine. CEO Renaud highlighted...
Why Do Weight Loss Drugs Work For Some And Not Others? It’s In The Genes
New research links genetic variants in the GLP‑1 and GIP receptors to the wide range of responses seen with obesity drugs. A common GLP‑1 receptor allele adds about 1.7 lb of weight loss per copy, while a GIP‑receptor variant eliminates the...
#AACR26 Preview: Revolution Medicines, the RAS Bonanza and China ADC Standouts
Revolution Medicines unveiled a pan‑RAS inhibitor that doubled overall survival for patients with recurrent or treatment‑resistant pancreatic cancer. The Phase 2 trial reported a median overall survival of roughly 12 months versus six months with standard chemotherapy. Data were presented at...
New Treatment Lets 3 Transplant Patients Halt Anti-Rejection Drugs
Researchers at the University of Pittsburgh infused donor‑derived immune cells into liver‑transplant recipients, aiming to induce immune tolerance. In an early‑stage trial of eight patients, three have remained off immunosuppressive drugs for over three years with stable graft function. The...
Adaptogen Supplements May Ease Stress and Anxiety and Boost Sleep Quality: RCT
A randomized, double‑blind trial of 186 stressed adults showed that both a multi‑herb adaptogen blend and a full‑spectrum ashwagandha extract significantly lowered perceived stress and improved sleep quality compared with placebo. The multi‑herb formula produced stronger, sustained mood benefits, while...
Establishing Impurity Specifications for Antibiotics
The FDA released a draft Level 1 guidance titled “Establishing Impurity Specifications for Antibiotics.” It offers non‑binding recommendations on setting organic impurity limits for antibiotics produced by fermentation or semi‑synthesis. The guidance applies to new drug applications, abbreviated new drug applications,...
Morgan Stanley Updates Bicycle Therapeutics Plc (BCYC) Outlook Amid Pipeline Refocus
Morgan Stanley cut its price target for Bicycle Therapeutics plc (BCYC) to $12 from $13 while maintaining an Equal‑Weight rating, citing the company’s strategic refocus on BT5528 and next‑generation Bicycle conjugate programs. The revision also reflects a roughly 30% workforce...